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Preclinical update on regulation 
of intracranial pressure in relation to idiopathic 
intracranial hypertension
Sajedeh Eftekhari* , Connar Stanley James Westgate, Maria Schmidt Uldall and Rigmor Hoejland Jensen
Abstract 
Background: Elevated intracranial pressure (ICP) is observed in association with a range of brain disorders. One 
of these challenging disorders is idiopathic intracranial hypertension (IIH), characterized by raised ICP of unknown 
cause with significant morbidity and limited therapeutic options. In this review, special focus is put on the preclinical 
research performed in order to understand the pathophysiology behind ICP regulation and IIH. This includes cerebro-
spinal fluid dynamics, molecular mechanisms underlying disturbances in brain fluids leading to elevated ICP, role of 
obesity in IIH, development of an IIH model and ICP measurements in rodents. The review also discusses existing and 
new drug targets for IIH that have been evaluated in vivo.
Conclusions: ICP monitoring in rodents is challenging and different methods have been applied. Some of these 
methods are invasive, depend on use of anesthesia and only allow short-term monitoring. Long-term ICP record-
ings are needed to study IIH but existing methods are hampered by several limitations. As obesity is one of the most 
common risk factors for IIH, a rodent obese model has been developed that mimics some key aspects of IIH. The 
most commonly used drugs for IIH have been evaluated in vivo for their efficacy at lowering ICP in the existing animal 
models. These studies suggest these drugs, including acetazolamide, might have limited or no reducing effect on ICP. 
Two drug targets that can impact ICP in healthy rodents are topiramate and a glucagon-like peptide-1 receptor (GLP-
1R) agonist. However, it remains to evaluate their effect in an IIH model with more precise and valid ICP monitoring 
system. Therefore, continued evaluation in the preclinical research with refined tools is of great importance to further 
understand the pathophysiology behind disorders with raised ICP and to explore new drug targets.
Keywords: Intracranial pressure, In vivo, Idiopathic intracranial hypertension, Choroid plexus, Cerebrospinal fluid 
regulation
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Introduction
Intracranial pressure and idiopathic intracranial 
hypertension
Elevated intracranial pressure (ICP) is observed in asso-
ciation with a range of brain disorders and their under-
lying pathophysiology is widely unknown. Actually, there 
is limited insight into the regulatory mechanisms of this 
essential balance under normal conditions and conse-
quently also a significant lack of specific treatments. In 
this review, we aim to focus on the preclinical research 
behind ICP regulation mainly with Idiopathic Intracra-
nial Hypertension (IIH) as a disease model. Further, we 
aim to discuss the existing and novel drug targets for IIH 
that have been evaluated in preclinical models.
The regulation of ICP is fundamental for providing 
a stable environment to enable normal brain function. 
According to the anatomists Monro and Kellie, ICP is 
determined by three parameters; the volume of the brain, 
cerebral blood volume and cerebrospinal fluid (CSF) vol-
ume, where cerebral blood volume and CSF are homeo-
statically controlled and compensate for acute changes in 
ICP [1]. Several cerebral pathologies of raised ICP exist 
which have profound consequences for the patients, such 
Open Access
Fluids and Barriers of the CNS
*Correspondence:  Sajedeh.eftekhari@regionh.dk
Danish Headache Center, Department of Neurology, Glostrup 
Research Institute, Rigshospitalet-Glostrup, University of Copenhagen, 
Nordstjernevej 42, 2600 Glostrup, Denmark
Page 2 of 12Eftekhari et al. Fluids Barriers CNS           (2019) 16:35 
as: traumatic brain injury (TBI), ischemic stroke, brain 
tumor, hepatic encephalopathy, hydrocephalus and IIH. 
IIH is a rare disease with an incidence of 4.7 per 100,000 
in the UK, where the disease predominantly affects 
females (82%) [2]. Raised ICP is an obligatory symptom 
of IIH, thus it is apparent that ICP homeostasis is per-
turbed in IIH. The diagnosis of IIH eliminates second-
ary causes of raised ICP, consequently altered cerebral 
anatomy and altered brain blood volume are unlikely to 
be causative in IIH. As such, CSF dynamics in IIH must 
be perturbed, where CSF dynamics are a balance of CSF 
secretion and drainage [3, 4].
CSF secretion
Humans produce around 500  ml of CSF per day, filling 
CSF spaces to a volume of 120–150  ml, indicating an 
average secretion rate of around 20  ml/h. A portion of 
CSF is generated from cerebral interstitial fluid via the 
ependymal lining of the ventricles and the pia mater, 
likely through hydrostatic forces. However the majority 
of CSF is generated via the choroid plexus (CP), organs 
that reside in the cerebral ventricles and display the char-
acteristic asymmetrical distribution of ion transporters 
of fluid transporting epithelia (Fig. 1). Although it is clear 
that the activity of ion transporters such as the  Na+/K+ 
Fig. 1 CSF secretion modulation at the choroid plexus. Simplified schematics of choroid plexus epithelial (CPe) cells. (Left cell) CSF secretion at CPe 
cells, whereby the activity of carbonic anhydrase (CA) generates carbonic acid which dissociates to a proton and a bicarbonate ion, these drive the 
sodium/hydrogen exchanger (NHE) and anion exchanger (AE2) respectively, transporting sodium and chloride ions into CPe cells. Additionally the 
basolateral sodium bicarbonate transporter (NBCn1) transports bicarbonate and sodium ions into the cell. These provide the ionic gradients to drive 
both the  Na+/K+ ATPase and the NKCC1 channel to transport sodium into the ventricular spaces, this facilitates the osmosis of water via aquaporin 
1 (AQP1). Furthermore the action of NKCC1 independently draws water from the cytosol to the ventricular space. The mechanisms of basolateral 
water transport remain unelucidated. Blue arrows represent the movement of water. CPe cell to the right represents current and proposed drug 
targets for modulating CSF secretion at the choroid plexus where the majority directly modifies the transport or generation of ions. The exceptions 
lie with somatostatin receptor (SST) agonist octreotide whose function and effect on ICP are unclear, and glucagon like peptide 1 receptor 
(GLP-1R) agonist exenatide which inhibits  Na+/K+ATPase actity
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ATPase and the  Na+-K+-2Cl−-1 cotransporter (NKCC1) 
are fundamental in CSF secretion at the CP, and are tar-
geted clinically to reduce ICP (Fig.  1), the mechanisms 
underlying the transport of water at the CP are contro-
versial [5, 6]. It has been hypothesized that CSF secretion 
at the CP is predominantly driven by osmosis, facilitated 
by the expression of the water channel Aquaporin 1 
(AQP1). However, evidence suggests that this is not the 
case. The CP is relatively impermeable to water, which 
is likely explained by the predominantly apical expres-
sion of AQP1 on CP, preventing osmosis [7–9]. Indeed 
AQP1 knockout mice do not ameliorate CSF secre-
tion [10]. Additionally the CP secretes CSF against an 
osmotic gradient, further demonstrating that osmosis is 
likely not the primary driver of CSF secretion [11]. This 
secretion independent of osmosis is mediated by solute-
mediated water co-transport, via the NKCC1 transporter, 
which contributes to roughly 50% of CSF secretion in 
mice [6]. Although this accounts for the majority of 
water transport at the apical CP membrane, there is lit-
tle understanding as to how water is transported across 
the basolateral membrane of the CP, although it is likely 
mediated via solute mediated water co-transport [12].
CSF drainage
Where CSF is produced it must be drained in such a 
manner that is homeostatically maintained to prevent 
aberrant alterations in ICP. Although the mechanisms 
underlying the homeostasis and molecular aspects of 
CSF drainage have not been elucidated, the structures 
where CSF drainage occurs are clearly defined. The 
arachnoid granulations (AG) of the superior sagittal sinus 
are thought to drain CSF directly into the venous system 
[13]. The precise mechanism for CSF drainage at the AG 
is unknown and the contribution of AG to CSF drainage 
is unknown. It is hypothesized to be facilitated through 
either paracellular movement of water or the vacuolisa-
tion of CSF by the capsule cells of the AG [14]. However 
the lack of AG in rodents suggests that other modalities 
for CSF drainage exist.
It has been hypothesised that CSF can be drained via 
perivascular spaces that penetrate the parenchyma, 
termed glymphatics, in an Aquaporin-4 (AQP4) depend-
ent manner [15]. This glymphatic drainage could be aided 
via the proposed trans-ependymal CSF flow from the 
ventricles to the parenchyma [16]. Additionally, two dis-
tinct branches of the lymphatic system have been dem-
onstrated to drain CSF. The lymphatics of the nasal cavity 
have been demonstrated to drain CSF through the cri-
briform plate in a variety of mammals including humans 
and non-human primates [17, 18]. Additionally, dural 
lymphatics have the capability to drain CSF and that 
damage to them reduces CSF flow and drainage [19, 20].
Regulation of ICP and IIH
There are currently a limited number of studies that 
assess CSF dynamics in IIH. Several studies utilizing 
small cohorts of IIH patients identified an increased 
CSF flow rate through the cerebral aqueduct, indicat-
ing increased CSF secretion [21–23]. Studies utilizing 
isotope cisternography suggest that IIH patients have 
increased resistance to CSF drainage, however these find-
ings are not universal across IIH patients and could be 
confounded by increased venous sinus pressure [24–26].
Histological data from cortical biopsies of IIH patients 
showed increased AQP4 expression at astrocyte end feet, 
a constituent of the glymphatic drainage. This is sugges-
tive of an altered state of CSF clearance via the glym-
phatic system [27]. Furthermore this study identifies that 
IIH brains have astrogliosis, perhaps explaining previous 
findings that IIH patients have larger ICP wave forms 
compared to headache controls, which indicate reduced 
parenchymal compliance [27, 28]. In a recent study from 
the same group, they demonstrated dysfunction of the 
blood-brain barrier (BBB) by measuring the extent of 
extravasated fibrinogen in IIH patients compared to ref-
erence material [29]. This study suggests that there may 
be leakage of BBB in IIH patients [29]. Further research 
is needed to evaluate the possible changes of BBB in IIH 
patients and what might cause the leakage.
Although it is apparent that ICP and in particular CSF 
dynamics are altered in IIH, the current literature fails 
to elucidate conclusively whether IIH patients have CSF 
hypersecretion, reduced CSF drainage or a combination 
of these factors. Furthermore the studies do not address 
the etiology of the alterations they describe, consequently 
further studies are required.
ICP dynamics in IIH
The gold standard for measuring ICP in patients is 
by using an intracranial probe however, this requires 
neuro-surgical intervention with risk of infections. 
Lumbar puncture (LP) opening pressure measured dur-
ing an LP is less invasive however, the obtained ICP 
values are less accurate than the gold standard method, 
and can only provide a short-term pressure reading 
during the procedure. There are some LP measure-
ment methods that have been shown to be comparable 
to intraparenchymal ICP recordings [30–32]. The LP 
opening pressure is a common procedure in the diag-
nosis of IIH but is not always standardized. According 
to the latest consensus, the diagnostic criteria mandate 
a cut-off opening pressure of > 25 cm CSF (18.3 mmHg) 
for diagnosing IIH [4]. However, this absolute value 
for IIH diagnosis is widely discussed as most clinicians 
experience a ‘grey zone’ between 25 cm CSF and 30 cm 
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CSF, which may not be pathological [33]. Further, it is 
also recognized in the consensus that this cut-off value 
is based on a single LP measurement and it should be 
recognized that there is a diurnal and wide variation 
in CSF pressure in patients [4]. It also highly debated 
if the LP opening pressure may not provide the true 
steady-state pressure because of normal fluctuations in 
ICP. Although mean ICP may decrease with responsive 
treatments, it has been shown that IIH patients still had 
raised mean ICP wave amplitude compared to controls, 
suggesting that the pulsatile ICP may be more relevant 
than the static ICP in the diagnostic setting for patients 
with IIH [28]. Another issue is that there are no true 
reference values for ICP in healthy humans. In one 
study, ICP was investigated in healthy elderly people 
(60–82  years) with no psychiatric or neurologic disor-
ders and these values could be used as reference val-
ues in the elderly [34]. Otherwise, what is considered 
to be normal values of ICP is based on examinations 
in patients needing ICP monitoring due to suspected 
disturbance in ICP. In some clinical studies, a control 
group of patients considered to be “pseudonormal” 
have been used in order to better understand the ICP 
values in humans. From these studies, the effect of body 
posture on ICP differed between healthy and patients 
with conditions with elevated ICP, where in normal 
human physiology patients appeared to have more 
tightly regulated ICP when switching body posture 
[35, 36]. ICP reference values are currently estimated 
to be 7–15  mmHg in a horizontal position, however 
these values can be lower and negative and should be 
considered to be normal (supine position, mean ICP 
0.5  mmHg; vertical position, mean ICP −  3.7  mmHg) 
[37]. Further, it has also been demonstrated that the 
“pseudonormal” group of patients had higher night 
time ICP compared to day time during 24 h ICP moni-
toring [38]. In addition, the authors reported decrease 
of ICP with age across all ages [38]. The remaining 
question is if these values might be similar in healthy 
subjects. Since ICP monitoring in healthy subjects is 
ethically unacceptable, a study evaluating ICP regula-
tion with detailed waveform analysis in normal rodents 
would be of great value.
In rodents, ICP values have been reported to vary 
between 2 and 8  mmHg with a mean value around 
6  mmHg [39, 40]. In animal models with raised ICP 
such as hydrocephalus, TBI and stroke, ICP is raised to 
10–30 mmHg [39, 41, 42]. The question is to what extent 
ICP should be raised in an animal model of IIH. As an 
IIH model should not cause severe damage, we predict 
that mean ICP should be above 6–7 mmHg but probably 
not extending as high as in the severe cerebral trauma 
models.
IIH pathophysiology
As mentioned earlier, IIH is a challenging disease with 
increased ICP of unknown aetiology and was previously 
called benign intracranial hypertension or pseudotumor 
cerebri. The most disabling symptoms are chronic head-
ache, impaired vision due to optic nerve compression 
and cognitive impairment [43–45]. IIH occurs mainly 
in young female individuals, 3.5 in 100,000 in the gen-
eral population, but the incidence is rapidly increasing in 
the wake of the global obesity epidemic, with up to 20 in 
100,000 in the obese population [3, 46–48]. The higher 
incidence and increased awareness may have improved 
the visual prognosis, whereas disabling headaches and 
cognitive dysfunction persist and lifelong disability may 
be the result [45, 49, 50]. Recent clinical evidence sug-
gests the involvement of hormones, androgens and glu-
cocorticoids in IIH pathophysiology [3, 51, 52]. As many 
IIH patients are obese, they might also have increased 
risk factors for cardiovascular conditions. In one study 
it was shown that 56% of the IIH patients had hyperten-
sion [53]. However, control patients were not included 
and the hypertension might have been due to obesity. 
In a recent large matched cohort study, the risks of car-
diovascular disorders were evaluated in women with 
IIH compared to controls matched on BMI and age [54]. 
The risk of heart failure, ischemic heart disease, stroke/
transient ischemic attack (TIA), type 2 diabetes, and 
hypertension was shown to be increased in women with 
IIH (30). For hypertension, the crude incidence rate was 
14.1 per 1000 person-years in women with IIH and 9.2 
per 1000 person-years in those without IIH (30). The 
underlying mechanisms for these risk factors need to 
be evaluated. Interestingly, it has been suggested that 
hypertension may alter CP dynamics affecting CSF pro-
duction and causing BBB alterations [55]. Preclinical 
studies have demonstrated that hypertensive rats have 
variations in their CSF composition that could be due 
to CSF dysfunction, which may lead to blood-CSF bar-
rier disruption [56]. Furthermore, it has been shown that 
hypertensive rats have increased CSF secretion rate and 
CP blood flow [57]. Therefore, it remains to be clarified 
if and how hypertension may affect the CSF dynamics in 
IIH patients.
As the molecular regulation of CSF is not yet fully 
understood, there is a lack of understanding for many 
pathological conditions associated with abnormal CSF 
dynamics. Hence, diseases involving elevated ICP are 
generally poorly understood and managed, due to 
the lack of specific targeted treatment options. Medi-
cal interventions for IIH range from dietary therapy 
(weight loss) to diuretics and surgical CSF diversion [3]. 
In IIH patients with rapidly declining vision, CSF diver-
sion surgery may be necessary. Thereby, the majority of 
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the patients receive medications that may reduce CSF 
secretion and consequently reduce ICP. However, all the 
interventions for IIH are non-specific and hampered by 
side effects. The 2015 Cochrane review concluded there 
was insufficient evidence to determine which treatments 
are potentially beneficial in IIH [58]. Therefore, there 
remains an unmet medical need for effective treatments 
of IIH. This highlights the need for preclinical research 
using animal models to increase the understating of the 
pathophysiology behind IIH and to explore novel drug 
targets.
Role of obesity in IIH
IIH has a prominent association with both the female 
gender and obesity as 90% of patients with IIH are obese 
[3, 48, 59]. The risk of IIH also increases with increasing 
BMI. The greater amount of weight gain the year before 
symptom onset resulted in a greater risk of IIH [46]. 
Thereby, weight loss has been suggested as effective treat-
ment strategy as it can lower ICP and improves some 
IIH symptoms [60–62]. However, typically weight loss 
is not maintained, meaning IIH symptoms return. Bari-
atric surgery has been suggested as a therapy option for 
IIH patients but these studies have been done in smaller 
patients groups without proper controls, so more studies 
are needed here [63, 64]. A randomized controlled trial 
of bariatric surgery in IIH patients has been started with 
the aim to compare two methods of weight loss, bariat-
ric surgery and a dietary program, to see which offers 
the most effective sustainable treatment for IIH [65]. The 
trial is expected to be completed in 2022 (ClinicalTrials.
gov, NCT02124486).
There is also a strong association between abdomi-
nal fat deposition and health outcomes consequently 
adipose distribution in patients with IIH may be of rel-
evance [66]. It has been shown that preferential lower 
body fat accumulation occurs in IIH patients using waist-
hip ratios [67]. In a more recent study the gold standard 
dual-energy X-ray absorptiometry (DEXA) scanning 
technique was used to evaluate fat mass and distribution 
in IIH patients. In this study the authors found instead 
that IIH patients have a similar centripetal distribution 
of fat mass to patients with simple obesity [68]. These 
results raise the question whether it is the type of adipose 
tissue or its location that is of relevance for IIH. Adi-
pose tissue functions as an endocrine organ, secreting a 
myriad of factors including proinflammatory cytokines, 
chemokines and adipokines [66, 69]. Therefore, hormone 
secretion from adipose tissue may be implicated in IIH. 
As obesity is the most common risk factor for IIH, the 
impact of obesity on ICP in rodents has been evaluated 
by our group and is discussed below.
Development of a rodent IIH model
Currently there are very few animal models with ele-
vated ICP and they are associated with the induction of 
severe cerebral traumas such as subarachnoid hemor-
rhage, TBI, brain tumors, kaolin induced hydrocepha-
lus and cerebral ischemia [39, 42, 70–73]. Development 
of an intracranial hypertension model without causing 
severe damage would be a valuable tool to increase our 
knowledge regarding the molecular regulation of CSF 
and disorders affecting the CSF production/regulation 
such as IIH. A model for IIH could improve the knowl-
edge regarding the pathophysiology of this disorder as 
well as the molecular mechanisms behind elevated ICP 
in other conditions. So far only one model has been 
developed that mimics some aspects of IIH [74]. Since 
there is a strong association between obesity and IIH, a 
model for obesity-induced IIH has been developed [74]. 
Zucker rats have been used as an obesity model with a 
mutation in the leptin receptor gene causing hyper-
phagia [75, 76]. Our group has demonstrated that the 
Zucker rats have higher ICP compared to lean-rats, sug-
gesting that obesity may increase ICP [74]. At the end 
of the study, 28 days, the Zucker rats had an average of 
40% higher ICP with the tendency of the ICP to increase 
in parallel with increasing BMI. Interestingly, mRNA 
and protein expression of AQP1 in CP of the obese rats 
were elevated compared to lean rats however no differ-
ences in the expression of NA/K ATPase alpha 1 expres-
sion was observed [74]. Physiological factors known to 
potentially influence ICP such as mean arterial blood 
pressure (MABP), arterial blood gases, serum retinol and 
retinol binding protein 4 (RBP4) levels were investigated. 
The authors found no differences in these parameters 
between the obese rats and lean rats supporting that the 
increase in ICP was attributed to the obesity. Although 
the Zucker rats developed higher ICP, the question is if 
this a sufficient elevation to mimic the pathologically ele-
vated ICP observed in IIH. Further, the obesity observed 
in IIH patients is hypothesized to be diet-induced since 
weight loss is associated with improvement in some of 
the IIH symptoms. Therefore, it will be of great interest to 
study ICP levels in diet-induced obese rats, which share 
many characteristics with the common form of human 
obesity. In addition, it will be of great importance for a 
robust IIH model to also mimic other clinically relevant 
IIH symptoms such as papilledema and headache. Fur-
ther, researchers suggest that hormonal and metabolic 
factors play an essential role in the development of IIH 
and these co-factors also needs to be evaluated in animal 
models for IIH [3, 51, 66]. A recent study has also high-
lighted the role of androgen excess in IIH patients show-
ing that female IIH patients had increased testosterone in 
both serum and CSF [52]. The in vitro data demonstrated 
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that testosterone is able to enhance the activity of  Na+/
K+-ATPase at the CP, suggesting that testosterone may 
modulate CSF secretion [52]. It remains to evaluate the 
effects of testosterone in vivo to elucidate its impact on 
ICP and as a driver for IIH.
ICP measurements in animal research
Another fundamental factor in the development of an 
IIH animal model is the ability to perform long-term 
ICP measurements in rodents. ICP measurements are 
widely used for diagnostic purposes and to inform treat-
ment options for conditions with raised ICP such as IIH. 
However, the invasive nature of performing ICP monitor-
ing in humans limits clinical research. Thereby, there is 
a great need of consistent and precise ICP recording in 
animal models, where ICP can be measured across the 
day, in response to a drug and during disease develop-
ment. However, it has been very challenging to meas-
ure ICP accurately in animal models due to the lack 
of refined equipment designed specifically to measure 
ICP in rodents. Various locations and techniques for 
measuring ICP have been investigated such as epidural, 
subdural, ventricular cisterna magna placement using 
a cannula, fluid-filled catheter or fiber-optic pressure 
transducers [77–86], summarized in Table  1. Lumbar 
cannulation has also been investigated in rodents [86, 
87]. The intraventricular technique in the preclinical set-
ting is very invasive and causes severe complications such 
as infections and degeneration of the cerebral tissue, so 
only short-term monitoring is possible. Therefore, sub-
dural and epidural cannulations are mostly used for ICP 
measurements in animal models. We have developed a 
novel method for long-term monitoring of ICP in rats 
from epidural space using fluid-filled catheter [40]. This 
study demonstrated that the epidural ICP recordings cor-
related exceptionally well with ventricular ICP with no 
complications as observed with the ventricular probes 
[40]. In the rats implanted with ventricular ICP probes, 
the probes lost patency and many of the animals devel-
oped symptoms of neurological malfunction, infections 
and/or displayed general signs of illness. At post mortem 
brain examination, hydrocephalus was observed in the 
rats with the ventricular probes [40]. We found that the 
epidural probes were less invasive with no tissue damage. 
These results suggest that the ventricular cannulation 
for ICP recordings may not be suitable for research pur-
poses investigating molecular changes in ICP and CSF 
production. This study is also the longest ICP monitor-
ing performed in rats, for up to 59  days. However, ICP 
recordings could not be performed daily and therefore 
the ICP recordings were performed on selected days with 
a total of 6 recordings.
Although the implementation of epidural ICP recording 
using fluid-filled systems has been a major improvement 
for measuring ICP in rodents, this method has some limi-
tations. In this method the transducer is not permanently 
implanted, which prevents the possibility of continuous 
ICP recordings over larger time intervals. Furthermore, 
this ICP method as the others depends on repeated use 
of anesthesia/sedation before each recording to immobi-
lize the animals which are additional cofounders affecting 
ICP. Additionally, the fluid-filled systems can develop air 
bubbles, resulting in false ICP values. Fiber-optic pressure 
transducers have been used to avoid these problems, how-
ever, it has only been developed for animals under anes-
thesia [79]. Telemetry devices using fluid-filled systems 
were developed in order to measure small changes in ICP 
and with the aim to develop a system for freely moving 
animals. This kind of telemetry has been used in rodents 
however ICP monitoring in freely moving rats was limited 
to 2–7 days [78, 88, 89].
Table 1 Overview of  preclinical studies using different 
methods to measure ICP in rat models
a Indicates that the rats where anesthetized/sedated during ICP measurements
b Indicates continuous 24/7 ICP measurements
Refs. Measuring site Measuring period Method
[122] Cisterna  magnaa 4 days Fluid-filled system
[83] Cisterna  magnaa Unknown Fluid-filled system
[84] Cisterna  magnaa 1.5 h Fluid-filled system
[123] Cisterna  magnaa
Ventriculara
1 h Fluid-filled system
[40] Ventricular and 
 epidurala
59 days Fluid-filled system
[81] Ventricular Unknown Fluid-filled system
[124] Ventricular 28 days Fluid-filled system
[94] Subarachnoid 
 spacea
4 h Fluid-filled system
[87] Lumbar 
 cannulationa
25 h Fluid-filled system
[125] Lumbar 
 cannulationa
25 h Fluid-filled system
[125] Subdurala 7 days Fluid-filled system
[77] Epidurala 6 h Fluid-filled system
[126] Epidurala 1 h Fluid-filled system
[123] Parenchymaa 1 h Fiber-optic transducer
[86] Parenchymaa 14 days Fiber-optic transducer
[127] Parenchyma 20 h Fiber-optic transducer
[85] Parenchymaa 3 h Fiber-optic transducer
[88] Ventriculara 7 days Telemetric device
[128] Ventricular 2–10 days Telemetric device
[78] Epidural 5 days Telemetric device
[41] Ventricularb 6 days Telemetric device
[90] Ventricularb 5 days Telemetric device
[39] Subduralb 28 days Telemetric device
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Recently, telemetric probes with specific ICP transduc-
ers have been developed to measure ICP continuously 
in freely moving rats (Kaha Sciences) [39]. This has a 
number of clear advantages compared to other avail-
able options in the field; it allows long-term recordings 
under conditions unhindered by anesthesia or restraint. 
So far this system has only been used in few studies, one 
in healthy male rats with continuous ICP monitoring for 
28  days and two in a TBI model with ICP continuously 
monitored for 5–6  days [39, 41, 90]. Since this system 
does not require any use of anesthesia/sedation for ICP 
recording, it may be very useful to study drug effects 
without any impact from additional confounders. It is 
important to be aware that in all the in vivo drug studies 
discussed below, anesthesia/sedation was used in order 
to measure ICP and the recordings were not performed 
continuously.
Drug targets for IIH
Acetazolamide
In the management of IIH, the focus is on reducing the 
elevated ICP by pharmacological therapy. Given that IIH 
patients often suffer from visual disturbances and head-
ache, management of IIH has been focused on preserv-
ing vision and reducing headache morbidity [4]. In this 
case, acetazolamide is the most commonly used drug 
for treatment of IIH. This drug is a carbonic anhydrase 
(CA) inhibitor that is believed to reduce CSF secretion 
and ICP via action on the CP by reducing ion transport 
consequently water across CP (Fig.  1). It has been sug-
gested that acetazolamide may decrease CSF secretion by 
55% in rats [91] and at similar rates in rabbits [92]. While 
some clinical studies have demonstrated a beneficial 
effect in IIH, it has limited efficacy, poor tolerability, and 
unresolved target mechanisms. Therefore, it is of great 
value to study the effect of this drug in preclinical mod-
els to understand its mechanisms and possible effects. 
In healthy rats, we have shown that a single high dose 
of acetazolamide (200  mg, given i.p.) lowered ICP and 
modulated the CSF secretion pathway [93]. Interestingly, 
we found that AQP1 and Na/K ATPase protein were 
increased in the membrane of CP epithelial cells, which 
could be a compensatory mechanism for the reduced ICP. 
In support, an older study also demonstrated that aceta-
zolamide given as intravenous infusion in rats caused a 
reduction in ICP [94]. However, another study showed 
that intra-arterial injections of acetazolamide reduced 
ICP, whereas intraventricular injection had no effect [95]. 
Thus it seems that the administration route and dose 
of acetazolamide is important for studying its effect on 
ICP. In a recent study, a clinically relevant dose of aceta-
zolamide was tested in rats via different administration 
routes [96]. The low dose of acetazolamide (103.3 mg/kg) 
that was equivalent to a single human dose (1  g) and a 
high dose (413.4 mg/kg) equivalent to a human daily dose 
(4 g) were administered either subcutaneously or orally. 
Neither the low nor the high dose of acetazolamide sig-
nificantly lowered ICP [96]. Using the most clinically 
relevant delivery route for acetazolamide, oral adminis-
tration, the drug lowered blood pH and induced diuresis 
in the rats, however it did not change ICP [96]. In this 
study, the authors used 4% NaCl as appropriate vehicle 
control as hypertonic solutions can lower ICP. This might 
explain the conflicting results from previous studies. In 
support of this study, in a rodent stroke model, aceta-
zolamide (50 mg/kg) given i.p. improved the pathological 
ICP spikes but it did not impact in the mean ICP levels 
or the outcome [97]. However, in all these studies only a 
single dose of acetazolamide was examined. Therefore, 
it is of great importance to examine if repeated clinical 
doses of acetazolamide might lower ICP as IIH patients 
often need repeated dosing of acetazolamide. In another 
condition with raised ICP, treatment with acetazolamide 
had no effect on clinical signs or ventricular volume in 
dogs with internal hydrocephalus [98]. Importantly, in 
clinical studies, treatment with acetazolamide resulted 
in symptom improvements such as visual field function 
in IIH patients with mild visual loss [99, 100]. In the ani-
mal studies, only the direct effects on ICP were studied, 
as a proper IIH animal model with related symptoms is 
missing. Therefore, it remains to investigate the effects 
of acetazolamide in a pathological condition mimicking 
IIH in vivo. Although acetazolamide is the most common 
used drug for IIH, the support for its efficacy on lower-
ing ICP is inconclusive. As many patients do not tolerate 
the drug due to all its severe side effects, it is even more 
important to further evaluate the effect of this drug and 
its use for IIH.
Topiramate
Topiramate was originally used for epilepsy treatment 
and as a migraine prophylactic drug [101, 102]. Topira-
mate has many mechanisms of action via activity on 
four protein complexes that are regulated by protein 
kinase phosphorylation: voltage-gated sodium channels, 
high voltage-gated calcium channels, GABA receptors, 
and AMPA/kainate receptors [102]. In addition, topira-
mate is a CA inhibitor similar to acetazolamide (Fig.  1) 
and has therefore become of interest for IIH treatment. 
Topiramate is of interest for IIH headache treatment, 
given that topiramate is an effective migraine prophylac-
tic and that many IIH patients suffer from severe head-
ache. In addition, topiramate can induce favorable and 
welcomed weight loss which is of benefit for treating IIH 
patients [103]. There are some clinical case studies that 
have shown efficacy of topiramate for IIH symptoms 
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[104–107]. Compared to acetazolamide, topiramate 
has higher carbonic anhydrase isoform specificity and 
increased lipophilic nature, which suggest better phar-
macological activity than acetazolamide. However, in an 
open label study, it was shown that topiramate improved 
IIH symptoms but no differences were found compared 
to acetazolamide treatment [108]. In a recent preclini-
cal study, it was however shown that topiramate signifi-
cantly lowered ICP in healthy rats while acetazolamide 
did not reduce ICP [96]. Topiramate was tested at both 
clinical low and high doses, which lowered ICP levels by 
32% and 21% respectively in healthy rats [96]. It remains 
to elucidate the effect of this drug on ICP in animal mod-
els with raised ICP and evaluate its effect of daily dosing 
as performed in the clinical studies. Although topiramate 
might have beneficial effects for IIH patients, this drug 
causes serious side effects such as cognitive impairment, 
insomnia, paraesthesia, fatigue and anxiety. This drug 
may therefore not be a better treatment option for IIH 
than acetazolamide.
Amiloride and furosemide
Diuretic agents have long been known to reduce CSF 
secretion and have therefore been regarded as a treat-
ment option for IIH (Fig. 1). One of these agents is furo-
semide, which blocks the cotransporter NKCC1 on CP 
epithelial cells. Furosemide has shown to reduce CSF 
secretion in various species [92, 109–111]. Furosemide 
has usually been used in combination with mannitol, 
where the combination has shown to reduce ICP [112, 
113]. It has also been tested in combination with 3% 
hypertonic saline which reduced ICP in patients with 
ICP > 20 mmHg [114]. A rat study showed that furosem-
ide alone did not affect plasma osmolality or brain water 
content at different doses, however it enhanced the effect 
of mannitol with greater reduction of brain water content 
[115]. When furosemide was given alone at high dose or 
low dose, this drug did not significantly reduce ICP in 
rats [96]. Another diuretic agent that is able to reduce 
CSF secretion is amiloride which inhibits the  Na+/H+ 
exchanger and/or  Na+ channels on the CP epithelial cells 
[116, 117]. One study has shown that amiloride reduced 
ICP in experimental brain edema in rats [118]. However, 
another study in healthy rats showed that amiloride and 
furosemide did not change ICP [96]. Clinical studies 
evaluating the efficacy of furosemide or amiloride for the 
treatment of IIH do not exist.
Octreotide
Octreotide is a synthetic somatostatin analogue and a 
potent inhibitor of growth hormone. Two uncontrolled 
clinical studies have shown its efficacy for IIH treat-
ment [119, 120]. In an in vivo study in rats a single dose 
of octreotide had no effect on ICP [96]. However, in the 
clinical studies, octreotide was given daily to IIH patients 
during the first months following diagnosis which might 
be necessary to significantly reduce ICP. Therefore, it will 
be of great interest to study repeated dosing of octreotide 
in animal studies.
GLP‑1R agonists
Glucagon-like peptide-1 receptor (GLP-1R) agonists are 
used to treat diabetes and promote weight loss. Due to 
its ability to affect fluid homeostasis in the kidney, we 
investigated if the GLP-1R agonist, exendin-4, could 
modulate CSF secretion and reduce ICP in rats [42]. This 
study demonstrated expression of GLP-1R in human and 
rat CP, and its ability to reduce  Na+- and  K+-dependent 
adenosine triphosphatase activity in cell cultures. Sub-
cutaneous injections with exendin-4 showed a reduc-
tion in ICP in both healthy and hydrocephalic rats [42]. 
Importantly, a single subcutaneous injection of exendin-4 
maintained lower ICP for 24 h. These results suggest that 
GLP-1R agonists may provide an alternative treatment 
for raised ICP conditions. It will be of great importance 
to investigate the effect of exendin-4 in an IIH animal 
model as the pathophysiology is very different from 
hydrocephalus. In another study it was shown that treat-
ment with the GLP-1 analogue, Liraglutide, significantly 
reduced cerebral edema after experimental TBI [121]. 
Taken together, a clinical study investigating the effect of 
GLP-1R agonists on ICP in humans is highly needed.
Conclusions
The role of obesity on ICP regulation has been evalu-
ated in vivo and lead to the first animal model mimicking 
some aspects of IIH. However, a refined model is needed 
to further investigate the mechanism behind IIH and also 
to provide valuable new knowledge regarding both regu-
lation and dysregulation of CSF and ICP dynamics. The 
most used drugs in the management of IIH have been 
evaluated in rodents and although with some limitations, 
some of these are not efficient for lowering ICP. How-
ever, their effect on IIH-related symptoms such as visual 
outcome and headache has not been evaluated in animal 
models. Preclinical research suggests a GLP-1R agonist 
as a novel drug target for elevated ICP which needs to be 
further evaluated. Furthermore, a novel ICP monitoring 
system has been developed for long-term ICP monitor-
ing in freely moving animals, which is a prerequisite to 
resolve the molecular origin of IIH-elevated ICP and to 
evaluate drug targets. In conclusion, preclinical inves-
tigations including the development of adequate in vivo 
models are warranted in order to increase our under-
standing in IIH pathophysiology and to explore novel 
drug targets able to reduce ICP.
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